Ilex Medical Ltd (ILX) Fair Value & Analysis
Healthcare · Il · Market cap 538M ILA
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 29 days ago
Share price −1.9% over the past month.
A solid business, screening 89% undervalued on our models.
What matters now
- The price is below even our cautious bear case (64.08 ILA). The market is more pessimistic than our downside scenario.
- Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (64.08 ILA to 117.79 ILA) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range 47.21 ILA – 151.16 ILA · fair‑value band 64.08 ILA – 117.79 ILA · the 49.79 ILA price screens below the 94.10 ILA fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Ilex Medical Ltd (ILX) currently trades at 49.79 ILA, while our model-based Fair Value estimate is 94.10 ILA, implying the stock looks roughly 89.0% undervalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Ilex Medical Ltd generated revenue of 906M ILA at a net margin of 5.7%. Revenue declined 10.4% year over year. It earns a return on equity of 7.8%. The balance sheet holds a net cash position of 129M ILA. Fundamentals as of Jul 12, 2026
Our scenario range runs from 64.08 ILA (bear case) to 117.79 ILA (bull case); at 49.79 ILA, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 89%, ILX screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (96.73 ILA) versus Dividend Discount (14.81 ILA). Highest evidence: Growth DCF (80).
Notify me when ILX reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 39
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Ilex Medical Ltd engages in the import, marketing, distribution and sale of medical laboratory equipment and various diagnostic products, diagnostic systems, and kits and consumables in Israel, the United States, and internationally.
Full company description
Ilex Medical Ltd engages in the import, marketing, distribution and sale of medical laboratory equipment and various diagnostic products, diagnostic systems, and kits and consumables in Israel, the United States, and internationally. The company also provides laboratory services, as well as is involved in the development, production, marketing and sale of software systems for information management in medical laboratories. Its products are used for performing tests in hospital medical laboratories, blood banks and health insurance funds, as well as for providing application and technical services to users. Ilex Medical Ltd was incorporated in 1990 and is based in Petah Tikva, Israel.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ilex Medical Ltd reported revenue of 931M ILA in FY2025 versus 1.1B ILA in FY2021, a compound −3.2%/yr. Reported net income was 55.6M ILA in FY2025, compounding −27.2%/yr from FY2021.
of which total revenue +7.5 pp · buybacks/dilution −1.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch ILX: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Ilex Medical Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ilex Medical Ltd (ILX) overvalued or undervalued?
What is the fair value of ILX?
What is the quality score of ILX?
What is the revenue of Ilex Medical Ltd (ILX)?
What is the net profit margin of ILX?
Does Ilex Medical Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Ilex Medical Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.